N-琥珀酰亚胺基 N-甲基氨基甲酸酯 | 18342-66-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-琥珀酰亚胺基 N-甲基氨基甲酸酯
• 中文别名: N-琥珀酰亚胺基-N-甲基氨基甲酸酯；N-琥珀酰亚胺基N-甲基氨基甲酸酯；O-琥珀酰亚胺基-N-甲基氨基甲酸酯
• 英文名称: 2,5-dioxopyrrolidin-1-yl methylcarbamate
• 英文别名: N-succinimidyl N-methylcarbamate；2,5-dioxopyrrolidin-1-yl N-methylcarbamate；O-succinimidyl N-methylcarbamate；succinimidyl N-methylcarbamate；SNMC；(2,5-dioxopyrrolidin-1-yl) N-methylcarbamate
• CAS: 18342-66-0
• 化学式: C₆H₈N₂O₄
• mdl: MFCD00800292
• 分子量: 172.141
• InChiKey: XMNGSPOWUCNRMO-UHFFFAOYSA-N

物化性质

• 熔点：
  148-153 °C
• 密度：
  1.41±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于二氯甲烷（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2925190090
• 安全说明：
  S26,S36
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  | 2-8°C |

反应信息

• 作为反应物：
  描述：

  N-琥珀酰亚胺基 N-甲基氨基甲酸酯 在 吡啶 、 亚硝酰氯 作用下， 反应 0.5h， 以98%的产率得到(2,5-二氧代吡咯烷-1-基)N-甲基-N-亚硝基氨基甲酸酯
  参考文献：
  名称：

  Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas

  摘要：

  A practical and convenient method for synthesizing antitumor compounds, N-alkyl-N-nitrosoureas, regioselectively nitrosated on the nitrogen atom bearing the alkyl group is proposed. N-Alkyl-N-nitrosocarbamates are interesting intermediates in these syntheses and yield, by reaction with amino compounds, the regioselectively nitrosated N-alkyl-N-nitrosoureas. As an interesting example, N,N'-bis[(2-chloroethyl)nitrosocarbamoyl]cystamine, a new attractive oncostatic derivative, has been prepared. The cytotoxic activity of these various compounds were tested on L1210 leukemia.

  DOI：

  10.1021/jm00344a017
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 异氰酸甲酯 在 吡啶 作用下， 反应 24.0h， 以80%的产率得到N-琥珀酰亚胺基 N-甲基氨基甲酸酯
  参考文献：
  名称：

  Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas

  摘要：

  A practical and convenient method for synthesizing antitumor compounds, N-alkyl-N-nitrosoureas, regioselectively nitrosated on the nitrogen atom bearing the alkyl group is proposed. N-Alkyl-N-nitrosocarbamates are interesting intermediates in these syntheses and yield, by reaction with amino compounds, the regioselectively nitrosated N-alkyl-N-nitrosoureas. As an interesting example, N,N'-bis[(2-chloroethyl)nitrosocarbamoyl]cystamine, a new attractive oncostatic derivative, has been prepared. The cytotoxic activity of these various compounds were tested on L1210 leukemia.

  DOI：

  10.1021/jm00344a017

文献信息

• PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
  申请人：ANDERSON MARK B.

  公开号：US20100068197A1

  公开（公告）日：2010-03-18

  Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  揭示的是作为细胞毒性剂有效的I式化合物。本发明的化合物在治疗多种临床病况中是有用的，这些病况中发生异常细胞的不受控制的生长和扩散。
• Substituted piperidines as therapeutic compounds
  申请人：Speedel Experimenta AG

  公开号：EP2018862A1

  公开（公告）日：2009-01-28

  Described are compounds of the general formula (I) and pharmaceutically acceptable salt thereof, in which R2, R3, W,and X have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

  描述了一般式（I）的化合物及其药用可接受的盐，其中R2、R3、W和X的定义在描述中详细说明，作为β-分泌酶、半胱氨酸蛋白酶D、质体蛋白酶II和/或HIV蛋白酶抑制剂。
• [EN] TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS TRICYCLIQUES INHIBITEURS DE PI3K ET PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012082997A1

  公开（公告）日：2012-06-21

  Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

  具有抗癌活性、抗炎活性或免疫调节特性的Formula I的三环PI3K抑制剂化合物被描述。描述了使用Formula I的三环PI3K抑制剂化合物进行体外、原位和体内诊断或治疗哺乳动物细胞、生物体或相关病理条件的方法。Formula I化合物包括立体异构体、几何异构体、互变异构体和其药用可接受盐。虚线表示可选的双键，至少有一条虚线是双键。取代基如所述。
• Metal-Free Synthesis of Oxazolidine-2,4-diones and 3,3-Disubstituted Oxindoles via ICl-Induced Cyclization
  作者：Wei Yi、Xing-Xiao Fang、Qing-Yun Liu、Gong-Qing Liu

  DOI：10.1002/ejoc.201801250

  日期：2018.12.19

  A metal‐free method for the construction of oxazolidine‐2,4‐diones and oxindoles is reported herein. The resulting products can be used as key intermediates in synthesis of bioactive compounds such as toloxatone, (±)‐esermethole, and (±)‐physostigmine.

  本文报道了一种无金属的方法制备恶唑烷-2,4-二酮和羟吲哚。所得产物可用作合成生物活性化合物（例如toloxatone，（±）-乙二胺和（±）-phystigtigmine）的关键中间体。
• [EN] AMINO ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDES AMINÉS
  申请人：PROXIMAGEN LTD

  公开号：WO2009007696A1

  公开（公告）日：2009-01-15

  Compounds of formula (I) or formula (II) have dopaminergic activity: wherein: R1 is a carboxyl, carboxyl ester, or carboxamide group; R2 is a group - C(=O)-NR3R4, or -S(=O)2-NR3R4; R3 and R4 are independently selected from hydrogen, optionally substituted C1-C6 alkyl, (C1-C5 fluoroalkyl)-CH2-, -Q, and -CH2Q, wherein Q is an optionally substituted monocyclic carbocyclic or heterocyclic ring of (3) to (6) ring atoms; or R3 and R4 together with the nitrogen to which they are attached form an optionally substituted monocyclic cycloalkyl or non-aromatic heterocyclic ring of (3) to (8) ring atoms; R5 is hydrogen, or a natural or non-natural alpha amino acid residue linked via a peptide bond; R6 is hydrogen or a group R7C(=O)-; and R7 is C1- C6 alkyl, C1-C6 fluoroalkyl or cyclopropyl.

  化合物的化学式（I）或化学式（II）具有多巴胺活性：其中：R1是一个羧基，羧酯基或羧酰胺基团；R2是一个基团-C（=O）-NR3R4，或-S（=O）2-NR3R4；R3和R4分别选自氢，可选择取代的C1-C6烷基，（C1-C5氟烷基）-CH2-，-Q和-CH2Q，其中Q是一个可选择取代的含（3）至（6）个环原子的单环碳环或杂环；或R3和R4与它们连接的氮一起形成一个可选择取代的含（3）至（8）个环原子的单环环烷基或非芳香杂环；R5是氢，或通过肽键连接的天然或非天然α氨基酸残基；R6是氢或一个基团R7C（=O）-；R7是C1-C6烷基，C1-C6氟烷基或环丙基。